 adopt immunotherapi lymphokine-activ killer cell recombin spontan pulmonari metastas syngen dun rat prostat tumor lymphokine-activ killer lak cell splenocyt rat weakli immunogen prostat tumor recombin maxim lak activ splenocyt rat tumor day incub u/ml./day day major lak cell high level asialo laminin surfac marker lak cell cytotox prostat tumor cell mous lymphoma vitro non-prost tumor cell normal rat splenocyt thymocyt splenocyt rat prostat tumor lak activ normal splenocyt winn type assay prostat tumor growth lak cell tumor cell lak ratio therapeut efficaci lak cell treatment primari solid prostat tumor pulmonari metastas rat lak cell combin therapeut benefit prevent prostat tumor metastas retard primari tumor growth regress pulmonari metastas prolong surviv untreat control group lak cell result studi conjunct therapeut approach surgic therapi primari solid tumor adopt immunotherapi lak cell vivo administr valuabl treatment prostat tumor spontan pulmonari metastas